How does generative chemistry work, and how can it help me?
The role of generative chemistry in drug discovery A key difficulty in finding new drugs is the sheer size of…
Optibrium demonstrates superior molecular docking method for small molecules and macrocycles
CAMBRIDGE, UK, 22 October 2024 – Optibrium, a leading developer of software and AI solutions for molecular design today announced…
Structure-based pose prediction: Non-cognate docking extended to macrocyclic ligands
In this paper, we describe an extended benchmark for non-cognate docking of macrocyclic ligands, and the superior performance of Surflex-Dock…
Molecular docking: Extrapolating to new scaffolds with Surflex-Dock
Interested in improving your binding mode predictions? Surflex-Dock is a unique method for molecular docking, offering automatic pipelines for ensemble docking, applicable to both small molecules and large peptidic macrocycles alike.
What’s the difference between QSAR and imputation predictive models – which method should I use and when?
We’re often asked, “What’s the difference between QSAR and imputation models?”, so I’m going to explain how the methods differ, their advantages and disadvantages, and when each approach is applicable.
How much does drug discovery software cost?
How number of users affect drug discovery software costs The number of people who need access to the platform is…
Cerella case studies ebook
In this ebook we demonstrate our deployable AI discovery platform, Cerella™. Browse real-world stories of success from our collaborations with AstraZeneca, Genetech, Takeda Pharmaceuticals, Constellation Pharmaceuticals and many more.
Challenges and approaches in 3D ligand-based drug design
Ann and Ajay discuss the science behind and applications of the eSim molecular similarity method, a ligand-based drug design approach which considers surface-shape, electrostatics, and directionally sensitive hydrogen-bonding when comparing two molecules.
Predicting routes of Phase I and II metabolism based on quantum mechanics and machine learning
This peer-reviewed paper in Xenobiotica describes a new method to determine the most likely experimentally-observed routes of metabolism and metabolites based on our WhichP450™, regioselectivity and new WhichEnzyme™ model.
Metabolism prediction, 3D virtual screening and more – meet StarDrop 7.5
We explore the exciting new features in the latest release of StarDrop, built to elevate your drug discovery projects. These include the all-new Metabolism module; high performance virtual screening; additional workflow improvements
2D structure alignment
Using the 2D structure alignment tool in StarDrop, define a substructure to perform a rigid alignment of molecules in the data set.
Matched series analysis
The objective in this worked example is to identify new derivatives that are likely to improve activity at their target, given the SAR already generated on a project.
Optibrium acquires BioPharmics LLC, expanding its 3D drug design and visualisation offering
BioPharmics’ Drs Ajay Jain (CEO) and Ann Cleves (Director of Applied Science) join the Optibrium team as Vice Presidents in the newly-created BioPharmics Division
A distributional model of bound ligand conformational strain: from small molecules to large peptidic macrocycles
We show that the distribution of expected global strain energy values is dependent on molecular size in a superlinear manner. The distribution of strain energy follows a rectified normal distribution whose mean and variance are related to conformational complexity.
Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning
Now, watch Matt Segall, PhD, CEO at Optibrium, as he introduces a real world case study where we applied deep learning to guide a project, in which potential compounds were displaying good activity profiles but the team wanted to improve their PK profile to achieve better efficacy.
Perspectives on generative chemistry – potential and reality
Have advances in AI and deep learning reached a threshold whereby generative chemistry methods are redefining drug design? This webinar…
Optibrium expands operations in North America for AI and computational drug discovery technologies
Establishment of Optibrium Inc. bolsters ongoing strategic Company growth and strenghtens direct US customer support. Dr Tamsin Mansley promoted to President of Optibrium Inc. to lead growing US-based team and business operations.
